Agios Pharmaceuticals Inc Q3 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gregory James Renza - RBC Capital Markets, Research Division - Analyst : This is (inaudible) on for Greg. Congrats on the progress. I have a question on AG-946. First, can you remind us -- and you mentioned earlier that there's a heterogeneity in the low-risk MDS. But can you remind us the difference between patients with transfused or low-burden transfusion REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 02, 2023 / 12:00PM, AGIO.OQ - Q3 2023 Agios Pharmaceuticals Inc Earnings Call versus high-burden of transition that we included in Phase 2b and why the mechanism of 946 could address more populations? And secondarily, there was questions on the bar for success earlier, but can you ask the question in a different way. I was wondering if we should look for those [processes of] early data with 30% to 40%, obviously, transfusion independent as a bar for competitiveness?

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : How are you thinking about the incremental commercial opportunity in pediatric PKD? How well are these patients characterized and what efforts remain on your end for identification? And would you expect a loss here to have a similar cadence to what you've seen in adults?

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : That's helpful. Are you able to provide any additional color on discontinuations at this point in the launch? And if you can't quantify it now, is there any time in the future where we'd be able to expect that?